Mizuho Has Lowered Expectations for Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price

Adaptimmune Therapeutics (NASDAQ:ADAP) had its price objective dropped by equities researchers at Mizuho from $3.00 to $1.50 in a research report issued on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Mizuho’s target price would suggest a potential upside of 106.90% from the stock’s current price.

A number of other research analysts have also recently issued reports on ADAP. HC Wainwright decreased their target price on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a research note on Thursday, November 14th. Guggenheim cut their price objective on Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Finally, StockNews.com cut Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $2.79.

Adaptimmune Therapeutics Trading Up 6.6 %

Shares of NASDAQ ADAP opened at $0.73 on Wednesday. Adaptimmune Therapeutics has a twelve month low of $0.42 and a twelve month high of $2.05. The stock has a market cap of $185.51 million, a price-to-earnings ratio of -3.30 and a beta of 2.26. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. The company’s fifty day moving average is $0.81 and its 200-day moving average is $1.00.

Institutional Trading of Adaptimmune Therapeutics

A number of institutional investors have recently modified their holdings of the company. Long Focus Capital Management LLC lifted its position in shares of Adaptimmune Therapeutics by 15.6% in the second quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company’s stock worth $12,037,000 after purchasing an additional 1,662,184 shares in the last quarter. Baillie Gifford & Co. lifted its position in Adaptimmune Therapeutics by 10.7% during the 3rd quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock worth $15,944,000 after buying an additional 1,626,657 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Adaptimmune Therapeutics during the 3rd quarter worth about $95,000. Renaissance Technologies LLC boosted its stake in shares of Adaptimmune Therapeutics by 28.3% during the 2nd quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock worth $1,742,000 after buying an additional 394,566 shares during the last quarter. Finally, Vontobel Holding Ltd. grew its holdings in shares of Adaptimmune Therapeutics by 230.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 30,000 shares in the last quarter. 31.37% of the stock is currently owned by institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.